Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Devoe

Nurse Practitioner Sioux Falls, SD Nurse Practitioner

NPI 1023489382 CMS profile 10531684

1305 W 18Th St, Sioux Falls, SD 57105

Open in the dashboard

General payments

$3,498

208 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Devoe of Sioux Falls, SD is reported in the CMS Open Payments database as having received $3,498 across 208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,304 78
2024 General $1,117 62
2023 General $586 36
2022 General $450 30
2021 General $42 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Devoe
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Nicole Devoe were reported at $1,304. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Nicole Devoe Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $42 $135 $40–$426 $132
2022 $450 $152 $48–$470 $149
2023 $586 $166 $54–$529 $160
2024 $1,117 $173 $55–$556 $164
2025 $1,304 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $869 52 payments
  2. Sun Pharmaceutical Industries Inc. $396 12 payments
  3. Janssen Biotech, Inc. $329 12 payments
  4. Amgen Inc. $271 17 payments
  5. Pfizer Inc. $260 27 payments
  6. Lilly USA, LLC $221 19 payments
  7. E.R. Squibb & Sons, L.L.C. $215 13 payments
  8. Genzyme Corporation $137 7 payments
  9. Novo Nordisk Inc $131 9 payments
  10. Grifols USA, LLC $78 4 payments
  11. Other $590 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,144 204 payments
  2. Education $354 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $329 12 payments
  2. RINVOQ $229 12 payments
  3. SKYRIZI $206 13 payments
  4. TALTZ $188 15 payments
  5. Otezla $187 12 payments
  6. ILUMYA $176 9 payments
  7. SOTYKTU $163 9 payments
  8. CIBINQO $149 19 payments
  9. DUPIXENT $137 7 payments
  10. UBRELVY $137 7 payments
  11. Other $2,107 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

322

Median for Nurse Practitioner: 389

Drug cost

$5,590

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 67 $1,264
Clobetasol Propionate Generic 33 $1,257
Triamcinolone Acetonide Generic 64 $1,000
Fluorouracil Generic 11 $689
Minocycline Hcl Generic 17 $485
Levothyroxine Sodium Generic 29 $245
Imiquimod Generic 12 $193
Mupirocin Generic 25 $147
Minoxidil Generic 35 $141
Escitalopram Oxalate Generic 16 $134

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$69,407

Of which drugs: $9,368

Medicare patients

415

Average age 74

Services billed

1,795

264 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 43%
Chronic kidney disease 22%
Diabetes 20%
Depression 18%
Ischemic heart disease 17%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 22 30 $9,335
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 44 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $202
$202 — —
RINVOQ
  • AbbVie, Inc. $185
$185 — —
TREMFYA
  • Janssen Biotech, Inc. $165
$165 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $133
$133 — —
TALTZ
  • Lilly USA, LLC $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record